Tetrahydrocannabinol (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tetrahydrocannabinol" in German language version.

refsWebsite
Global rank German rank
2nd place
3rd place
4th place
7th place
1st place
1st place
195th place
255th place
33rd place
2nd place
2,092nd place
164th place
68th place
29th place
800th place
160th place
2,393rd place
2,660th place
6,166th place
low place
5,817th place
506th place
1,137th place
74th place
low place
low place
2,628th place
166th place
low place
low place
8,614th place
583rd place
14th place
31st place

archive.today

bgbl.de

  • Fünfundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften (BGBl. 2011 I S. 821)

bund.de

bfr.bund.de

recht.bund.de

  • Fassung nach Art. 3 Gesetz zum kontrollierten Umgang mit Cannabis und zur Änderung weiterer Vorschriften (Cannabisgesetz - CanG) vom 27. März 2024, BGBl. 2024 I Nr. 109.

bundesregierung.de

bundestag.de

  • Götz Hausding: Bundestag lässt Cannabis-Arzneimittel für schwerkranke Patienten zu. In: Deutscher Bundestag. (bundestag.de [abgerufen am 12. Mai 2017]).

cannabis-med.org

  • Arno Hazekamp: Eine Beurteilung der Qualität von medizinischem Cannabis in den Niederlanden. In: Cannabinoids. Band 1, Nr. 1, 2006, S. 1–10. (PDF; 278 kB).

cannabisbureau.nl

doi.org

  • Edward R. Garrett, C. Anthony Hunt: Physicochemical Properties, Solubility, and Protein Binding of Δ9-Tetrahydrocannabinol. In: Journal of Pharmaceutical Sciences. Band 63, Nr. 7, 1974, S. 1056–1064, doi:10.1002/jps.2600630705.
  • R. N. Phillips, R. F. Turk, R. B. Forney: Acute toxicity of delta-9-tetrahydrocannabinol in rats and mice. In: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). Band 136, Nr. 1, 1971, S. 260–263, doi:10.3181/00379727-136-35241, PMID 5540621.
  • Robert B. Forney, Glenn F. Kiplinger: Toxicology and Pharmacology of Marijuana. In: Annals of the New York Academy of Sciences. Band 191, Nr. 1, 1971, S. 74–82, doi:10.1111/j.1749-6632.1971.tb13989.x.
  • Roger Adams, Madison Hunt, J. H. Clark: Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. In: Journal of the American Chemical Society. Band 62, Nr. 1, 1940, S. 196–200, doi:10.1021/ja01858a058.
  • Yehiel Gaoni, Raphael Mechoulam: Isolation, structure and partial synthesis of an active constituent of hashish. In: Journal of the American Chemical Society. Band 86, Nr. 8, 1964, S. 1646–1647, doi:10.1021/ja01062a046.
  • Lumír Ondřej Hanuš u. a.: Phytocannabinoids: a unified critical inventory. In: Nat. Prod. Rep. 33, 2016, S. 1357–1392, doi:10.1039/C6NP00074F
  • J. Jung, M. R. Meyer, H. H. Maurer, C. Neusüß, W. Weinmann, V. Auwärter: Studies on the metabolism of the Delta9-tetrahydrocannabinol precursor Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques. In: Journal of Mass Spectrometry. Band 44, Nr. 10, 2009, S. 1423–1433, doi:10.1002/jms.1624.
  • Laura J. Rovetto, Niccolo V. Aieta: Supercritical carbon dioxide extraction of cannabinoids from Cannabis sativa L.. In: The Journal of Supercritical Fluids. 129, 2017, S. 16, doi:10.1016/j.supflu.2017.03.014.
  • D. Gloss: An Overview of Products and Bias in Research. In: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. Band 12, Nummer 4, Oktober 2015, S. 731–734, doi:10.1007/s13311-015-0370-x, PMID 26202343, PMC 4604179 (freier Volltext) (Review).
  • M. A. Huestis: Pharmacokinetics and metabolism of the plant cannabinoids, Δ⁹-tetrahydrocannabinol, cannabidiol and cannabinol. In: Handbook of Experimental Pharmacology. Nr. 168, 2005, S. 657–690, doi:10.1007/3-540-26573-2_23.
  • The central neuropharmacology of psychotropic cannabinoids. In: Pharmacology & Therapeutics. Band 36, Nr. 2–3, 1988, S. 189–261, doi:10.1016/0163-7258(88)90106-4.
  • Roger G. Pertwee: Pharmacological and therapeutic targets for Δ9-tetrahydrocannabinol and cannabidiol. In: Euphytica. Band 140, Nr. 1–2, 2004, S. 73–82, doi:10.1007/s10681-004-4756-9.
  • Louisa Degenhardt: "Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis", doi:10.1016/S2215-0366(19)30401-8. Lancet Psychiatry journal, 28. Oktober 2019.
  • E. B. Oleson, J. F. Cheer: A brain on cannabinoids: the role of dopamine release in reward seeking. In: Cold Spring Harbor perspectives in medicine. Band 2, Nummer 8, 2012, S. , doi:10.1101/cshperspect.a012229. PMID 22908200, PMC 3405830 (freier Volltext) (Review).
  • Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, Rodriguez V, Jongsma HE, Ferraro L, La Cascia C, La Barbera D, Tarricone I, Berardi D, Szöke A, Arango C, Tortelli A, Velthorst E, Bernardo M, Del-Ben CM, Menezes PR, Selten JP, Jones PB, Kirkbride JB, Rutten BP, de Haan L, Sham PC, van Os J, Lewis CM, Lynskey M, Morgan C, Murray RM: The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. In: Lancet Psychiatry. 6. Jahrgang, Nr. 5, Mai 2019, S. 427–436, doi:10.1016/S2215-0366(19)30048-3, PMID 30902669, PMC 7646282 (freier Volltext).
  • J. A. McLaren, E. Silins, D. Hutchinson, R. P. Mattick, W. Hall: Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies. In: The International journal on drug policy. Band 21, Nummer 1, Januar 2010, S. 10–19, doi:10.1016/j.drugpo.2009.09.001. PMID 19783132 (Review).
  • S. Minozzi, M. Davoli, A. M. Bargagli, L. Amato, S. Vecchi, C. A. Perucci: An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. In: Drug and alcohol review. Band 29, Nummer 3, Mai 2010, S. 304–317, doi:10.1111/j.1465-3362.2009.00132.x. PMID 20565524.
  • T. H. Moore, S. Zammit, A. Lingford-Hughes, T. R. Barnes, P. B. Jones, M. Burke, G. Lewis: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. In: Lancet. Band 370, Nummer 9584, Juli 2007, S. 319–328, doi:10.1016/S0140-6736(07)61162-3. PMID 17662880.
  • R. Kuepper, P. D. Morrison, J. van Os, R. M. Murray, G. Kenis, C. Henquet: Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. In: Schizophrenia research. Band 121, Nummer 1–3, August 2010, S. 107–117, doi:10.1016/j.schres.2010.05.031. PMID 20580531.
  • M. Underner, T. Urban, J. Perriot, I. de Chazeron, J. C. Meurice: Cannabis smoking and lung cancer. In: Revue des maladies respiratoires. Band 31, Nummer 6, Juni 2014, S. 488–498, doi:10.1016/j.rmr.2013.12.002. PMID 25012035 (Review).
  • M. Joshi, A. Joshi, T. Bartter: Marijuana and lung diseases. In: Current opinion in pulmonary medicine. Band 20, Nummer 2, März 2014, S. 173–179, doi:10.1097/MCP.0000000000000026. PMID 24384575.
  • Luis Ribeiro, Philip W. Ind: Marijuana and the lung: hysteria or cause for concern? In: Breathe. Band 14, Nr. 3, September 2018, S. 196–205, doi:10.1183/20734735.020418, PMID 30186517, PMC 6118880 (freier Volltext).
  • Russell C. Callaghan, Peter Allebeck, Anna Sidorchuk: Marijuana use and risk of lung cancer: a 40-year cohort study. In: Cancer Causes & Control. Band 24, Nr. 10, Oktober 2013, S. 1811–1820, doi:10.1007/s10552-013-0259-0.
  • Frederike K. Engels, Floris A. de Jong u. a.: Medicinal cannabis in oncology. In: European Journal of Cancer. 43, 2007, S. 2638–2644, doi:10.1016/j.ejca.2007.09.010.
  • Sandra B. Grauwiler, Jürgen Drewe, André Scholer: Sensitivity and Specificity of Urinary Cannabinoid Detection with Two Immunoassays After Controlled Oral Administration of Cannabinoids to Humans. In: Therapeutic Drug Monitoring. Band 30, Nr. 4, 2008, S. 530–535, doi:10.1097/FTD.0b013e318180c7c2.
  • Richard A. Gustafson u. a.: Urinary cannabinoid detection times after controlled oral administration of Δ9-tetrahydrocannabinol to humans. In: Clinical Chemistry. Band 49, Nr. 7, 2003, S. 1114–1124, doi:10.1373/49.7.1114.
  • S. Strano-Rossi, F. Molaioni, F. Botrè: Rapid screening of drugs of abuse and their metabolites by gas chromatography/mass spectrometry: application to urinalysis. In: Rapid Communications in Mass Spectrometry. Band 19, Nr. 11, 2005, S. 1529–1535, doi:10.1002/rcm.1942.

drugabuse.gov

espacenet.com

worldwide.espacenet.com

  • Patent DE102005028937B4: Verfahren zur Herstellung von Dronabino. Angemeldet am 22. Juni 2005, veröffentlicht am 23. Juli 2009, Anmelder: Bionorica AG, Erfinder: Joachim Erler, Stefan Heitner.

europa.eu

echa.europa.eu

nih.gov

ncbi.nlm.nih.gov

  • R. N. Phillips, R. F. Turk, R. B. Forney: Acute toxicity of delta-9-tetrahydrocannabinol in rats and mice. In: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). Band 136, Nr. 1, 1971, S. 260–263, doi:10.3181/00379727-136-35241, PMID 5540621.
  • D. Gloss: An Overview of Products and Bias in Research. In: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. Band 12, Nummer 4, Oktober 2015, S. 731–734, doi:10.1007/s13311-015-0370-x, PMID 26202343, PMC 4604179 (freier Volltext) (Review).
  • J. J. Feigenbaum, F. Bergmann, S. A. Richmond, R. Mechoulam, V. Nadler, Y. Kloog, M. Sokolovsky: Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. In: Proceedings of the National Academy of Sciences. Band 86, Nummer 23, Dezember 1989, S. 9584–9587. PMID 2556719. PMC 298542 (freier Volltext).
  • E. B. Oleson, J. F. Cheer: A brain on cannabinoids: the role of dopamine release in reward seeking. In: Cold Spring Harbor perspectives in medicine. Band 2, Nummer 8, 2012, S. , doi:10.1101/cshperspect.a012229. PMID 22908200, PMC 3405830 (freier Volltext) (Review).
  • Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, Rodriguez V, Jongsma HE, Ferraro L, La Cascia C, La Barbera D, Tarricone I, Berardi D, Szöke A, Arango C, Tortelli A, Velthorst E, Bernardo M, Del-Ben CM, Menezes PR, Selten JP, Jones PB, Kirkbride JB, Rutten BP, de Haan L, Sham PC, van Os J, Lewis CM, Lynskey M, Morgan C, Murray RM: The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. In: Lancet Psychiatry. 6. Jahrgang, Nr. 5, Mai 2019, S. 427–436, doi:10.1016/S2215-0366(19)30048-3, PMID 30902669, PMC 7646282 (freier Volltext).
  • J. A. McLaren, E. Silins, D. Hutchinson, R. P. Mattick, W. Hall: Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies. In: The International journal on drug policy. Band 21, Nummer 1, Januar 2010, S. 10–19, doi:10.1016/j.drugpo.2009.09.001. PMID 19783132 (Review).
  • S. Minozzi, M. Davoli, A. M. Bargagli, L. Amato, S. Vecchi, C. A. Perucci: An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. In: Drug and alcohol review. Band 29, Nummer 3, Mai 2010, S. 304–317, doi:10.1111/j.1465-3362.2009.00132.x. PMID 20565524.
  • T. H. Moore, S. Zammit, A. Lingford-Hughes, T. R. Barnes, P. B. Jones, M. Burke, G. Lewis: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. In: Lancet. Band 370, Nummer 9584, Juli 2007, S. 319–328, doi:10.1016/S0140-6736(07)61162-3. PMID 17662880.
  • R. Kuepper, P. D. Morrison, J. van Os, R. M. Murray, G. Kenis, C. Henquet: Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. In: Schizophrenia research. Band 121, Nummer 1–3, August 2010, S. 107–117, doi:10.1016/j.schres.2010.05.031. PMID 20580531.
  • M. Underner, T. Urban, J. Perriot, I. de Chazeron, J. C. Meurice: Cannabis smoking and lung cancer. In: Revue des maladies respiratoires. Band 31, Nummer 6, Juni 2014, S. 488–498, doi:10.1016/j.rmr.2013.12.002. PMID 25012035 (Review).
  • M. Joshi, A. Joshi, T. Bartter: Marijuana and lung diseases. In: Current opinion in pulmonary medicine. Band 20, Nummer 2, März 2014, S. 173–179, doi:10.1097/MCP.0000000000000026. PMID 24384575.
  • Luis Ribeiro, Philip W. Ind: Marijuana and the lung: hysteria or cause for concern? In: Breathe. Band 14, Nr. 3, September 2018, S. 196–205, doi:10.1183/20734735.020418, PMID 30186517, PMC 6118880 (freier Volltext).
  • J. Wrege, A. Schmidt, A. Walter, R. Smieskova, K. Bendfeldt, E. W. Radue, U. E. Lang, S. Borgwardt: Effects of cannabis on impulsivity: a systematic review of neuroimaging findings. In: Current pharmaceutical design. Band 20, Nummer 13, 2014, S. 2126–2137. PMID 23829358, PMC 4052819 (freier Volltext).
  • A. Batalla, S. Bhattacharyya, M. Yücel, P. Fusar-Poli, J. A. Crippa, S. Nogué, M. Torrens, J. Pujol, M. Farré, R. Martin-Santos: Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. In: PloS one. Band 8, Nummer 2, 2013, S. e55821. PMID 23390554, PMC 3563634 (freier Volltext).
  • K. R. Müller-Vahl u. a.: Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. In: J Clin Psychiatry. 2003. PMID 12716250.
  • Lin L, Amaratunga P, Reed J, Huang P, Lemberg BL, Lemberg D: Quantitation of Δ8-THC, Δ9-THC, Cannabidiol and 10 Other Cannabinoids and Metabolites in Oral Fluid by HPLC-MS-MS., J Anal Toxicol. 2022 Feb 14;46(1):76-88, PMID 33270860.
  • Lo Faro AF, Venanzi B, Pilli G, Ripani U, Basile G, Pichini S, Busardò FP: Ultra-high-performance liquid chromatography-tandem mass spectrometry assay for quantifying THC, CBD and their metabolites in hair. Application to patients treated with medical cannabis., J Pharm Biomed Anal. 2022 Aug 5;217:114841, PMID 35636009.
  • Metz TD, McMillin GA, Silver RM, Allshouse AA, Heard K, Jensen TL, Wymore EM, Stickrath E, Conageski C, Kinney GL, Binswanger IA: Quantification of prenatal marijuana use: evaluation of the correlation between self-report, serum, urine and umbilical cord assays among women delivering at two urban Colorado hospitals., Addiction. 2022 Jan;117(1):172-181, PMID 34142398.
  • Zhao J, Lu J, Zhao H, Yan Y, Dong H, Li W: Illicit drugs and their metabolites in urban wastewater: Analysis, occurrence and consumption in Xinjiang, China., Sci Total Environ. 2022 Dec 15;852:158457, PMID 36063955.
  • González-Mariño I, Thomas KV, Reid MJ: Determination of cannabinoid and synthetic cannabinoid metabolites in wastewater by liquid-liquid extraction and ultra-high performance supercritical fluid chromatography-tandem mass spectrometry., Drug Test Anal. 2018 Jan;10(1):222-228, PMID 28371432.
  • Fitzgerald AH, Zhang Y, Fritz S, Whitehouse WH, Brabson T, Pohlman L, Cernicchiaro N, Tonozzi C, Ensley S: Detecting and quantifying marijuana metabolites in serum and urine of 19 dogs affected by marijuana toxicity, J Vet Diagn Invest. 2021 Sep;33(5):1002-1007, PMID 34247555.
  • B. Moosmann, N. Roth, V. Auwärter: Finding cannabinoids in hair does not prove cannabis consumption. In: Sci Rep. 5, 7. Okt 2015, S. 14906. PMID 26443501.
  • T.M. Lovestead and T.J. Bruno, Determination of Cannabinoid Vapor Pressures to Aid in Vapor Phase Detection of Intoxication. Forensic Chemistry. Published online 27 June 2017. PMID 29266138.
  • Sempio C, Wymore E, Palmer C, Bunik M, Henthorn TK, Christians U, Klawitter J: Detection of Cannabinoids by LC-MS-MS and ELISA in Breast Milk., J Anal Toxicol. 2021 Aug 14;45(7):686-692, PMID 33002141
  • González-Mariño I, Thomas KV, Reid MJ: Determination of cannabinoid and synthetic cannabinoid metabolites in wastewater by liquid-liquid extraction and ultra-high performance supercritical fluid chromatography-tandem mass spectrometry., Drug Test Anal. 2018 Jan;10(1):222-228., PMID 28371432

pharmazeutische-zeitung.de

redirecter.toolforge.org

  • Luigi L. Romano, Arno Hazekamp: Cannabis Oil: chemical evaluation of an upcoming cannabis-based medicine. In: Cannabinoids 2013;1(1):1-11. Archiviert vom Original am 15. Dezember 2017; abgerufen am 19. April 2019.
  • Europäischer Drogenbericht 2017. (PDF) Archiviert vom Original am 22. Juni 2017; abgerufen am 22. Februar 2023.

thelancet.com

web.archive.org

who.int